An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Stocks to Buy or Sell. In this article, we are going to take a look at where PepsiCo, Inc. (NASDAQ:PEP) stands against other ...

Jim Cramer in a latest program mentioned an analyst downgrade on The J. M. Smucker Company (NYSE:SJM) and reiterated that he ...

Doctors say that for many patients, these medications help them get control of their obesity and other weight-related medical issues, along with improving their blood sugar and heart health. However, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Gypsy-Rose Blanchard denied the 'false rumor' that CPS paid a visit to her home out of concern for her baby daughter Aurora, ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...